BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Debio 1562M readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Debio 1562M\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06969430-3027@assetmemo.bio
DTSTAMP:20261121T010122Z
DTSTART;VALUE=DATE:20311130
DTEND;VALUE=DATE:20311201
SUMMARY:Debio 1562M: Phase 1/2 readout est. (NCT06969430)
DESCRIPTION:Debio 1562M\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Stu
 dy to Assess the Safety\, Tolerability\, and Antileukemic Activity of Debi
 o 1562M in Participants With Acute Myeloid Leukemia (AML)\nEstimated prima
 ry completion: November 2031. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/debio-1562m#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06969430
URL:https://assetmemo.bio/drug/debio-1562m#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
